<abstract xmlns="http://www.w3.org/1999/xhtml"><p>Drug induced lupus erythematosus (DILE) is a syndrome that is formed by lupus-like symptoms and laboratory characteristics. Capecitabine is an orally administered tumor-selective fluoropyrimidine that acts as a prodrug of 5-Fluorouracil and bevacizumab is an antivascular endothelial growth factor (anti-VEGF) antibody, both are used for the treatment of patients with colorectal cancer. Herein we report the first case of DILE in a 68-year-old woman who presented with arthralgia, myalgia and prolonged thrombocytopenia after receiving capecitabine and bevacizumab combination treatment as palliative treatment for metastatic colon cancer. Platelet levels were increased and joint complaints disappeared in the first week of hydroxychloroquine and methylprednisolone treatment after chemotherapy had been discontinued. In conclusion, physicians should be alert to the possibility of DILE in patients presenting with thrombocytopenia under a capecitabine and bevacizumab chemotherapy regimen.</p></abstract>

Drug induced lupus erythematosus (DILE) is a syndrome that is formed by lupus-like symptoms and laboratory characteristics. Capecitabine is an orally administered tumor-selective fluoropyrimidine that acts as a prodrug of 5-Fluorouracil and bevacizumab is an antivascular endothelial growth factor (anti-VEGF) antibody, both are used for the treatment of patients with colorectal cancer. Herein we report the first case of DILE in a 68-year-old woman who presented with arthralgia, myalgia and prolonged thrombocytopenia after receiving capecitabine and bevacizumab combination treatment as palliative treatment for metastatic colon cancer. Platelet levels were increased and joint complaints disappeared in the first week of hydroxychloroquine and methylprednisolone treatment after chemotherapy had been discontinued. In conclusion, physicians should be alert to the possibility of DILE in patients presenting with thrombocytopenia under a capecitabine and bevacizumab chemotherapy regimen.

Drug Induced Lupus Erythematosus Due to Capecitabine and Bevacizumab Treatment Presenting with Prolonged Thrombocytopenia

Department of Medical Oncology, Erciyes University, Faculty of Medicine, Kayseri, Turkey

Department of Internal Medicine, Erciyes University, Faculty of Medicine, Kayseri, Turkey

Department of Rheumatology, Erciyes University, Faculty of Medicine, Kayseri, Turkey

Department of Internal Medicine, Selcuk University, Faculty of Medicine, Konya, Turkey

Department of Rheumatology, Ondokuz Mayıs University, Faculty of Medicine, Samsun, Turkey

Romanian Journal of Internal Medicine

This chapter is distributed under the terms of the Creative Commons Attribution 4.0 Public License.

Drug induced lupus erythematosus (DILE) is a syndrome that is formed by lupus-like symptoms and laboratory characteristics. Capecitabine is an orally...

Drug Induced Lupus Erythematosus Due to Capecitabine and Bevacizumab Treatment Presenting with Prolonged Thrombocytopenia

Data publikacji: 14 paź 2015

Zakres stron: 282 - 285

Otrzymano: 01 maj 2015

DOI: https://doi.org/10.1515/rjim-2015-0037

Słowa kluczowe
capecitabine, drug induced lupus erythematosus, thrombocytopenia

© 2015 Ersin Ozaslan et al., published by De Gruyter Open

This chapter is distributed under the terms of the Creative Commons Attribution 4.0 Public License.

Drug Induced Lupus Erythematosus Due to Capecitabine and Bevacizumab Treatment Presenting with Prolonged Thrombocytopenia

Data publikacji: 14 paź 2015

Zakres stron: 282 - 285

Otrzymano: 01 maj 2015

DOI: https://doi.org/10.1515/rjim-2015-0037

Słowa kluczowecapecitabine, drug induced lupus erythematosus, thrombocytopenia

© 2015 Ersin Ozaslan et al., published by De Gruyter Open

This chapter is distributed under the terms of the Creative Commons Attribution 4.0 Public License.

Słowa kluczowe
capecitabine, drug induced lupus erythematosus, thrombocytopenia